Clinical Trials
9 trialsNCT07302347 2026-06-05
MK-3475-G21
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05583708 2026-04-22
iPRRT
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT06947928 2026-04-17
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc.
Phase 2/3 Recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT05496036 2026-02-18
MCC
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT05859074 2025-12-03
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06940440 2025-10-15
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
TuHURA Biosciences, Inc.
Phase 1 Recruiting
NCT05086692 2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2 Recruiting